This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Claussen, M. Articles by Braulke, T. Search for Related Content PubMed PubMed Citation Articles by Claussen, M. Articles by Braulke, T.

Proteolysis of Insulin-Like Growth Factors (IGF) and IGF Binding Proteins by Cathepsin D¹

Institute for Biochemistry II, University of Göttingen, D-37073 Göttingen, Germany; and Metabolic Unit, Department of Medicine, University Hospital (J.Z.), CH-8091 Zürich, Switzerland

Address all correspondence and requests for reprints to: Thomas Braulke, Ph.D., Institute for Biochemistry II, University of Göttingen, Gosslerstrasse 12D, D 37073 Göttingen, Germany. E-mail: braulke{at}ukb2-00.uni-bc.gwdg.de

Various proteinases have been postulated to function in limited proteolysis of insulin-like growth factor binding proteins (IGFBPs) contributing to the regulation of IGF bioavailability. In this study, we report on the in vitro degradation of IGFs and IGFBPs by the purified acidic aspartylprotease cathepsin D that has been shown to proteolyze IGFBP-3. Recombinant human [¹²⁵I] IGFBP-1 to -5 were processed by cathepsin D to fragments of defined sizes in a concentration dependent manner, whereas IGFBP-6 was not degraded.

Ligand blotting revealed that none of the IGFBP-1 or -3 fragments formed by cathepsin D retain their ability to bind IGF. By N-terminal sequence analysis of nonglycosylated IGFBP-3 fragments produced by cathepsin D, at least four different cleavage sites were identified. Some of these cleavage sites were identical or differed by one amino acid from sites used by other IGFBP proteases described. The IGFBP-3 and -4 cleavage sites produced by cathepsin D are located in the nonconserved central region. IGF-I and -II, but not the unrelated platelet-derived growth factor BB, were degraded by cathepsin D in a time and concentration-dependent manner. We speculate that the major functional site of cathepsin D is intracellular and may be involved 1) in the selected clearance either of IGFBP or IGFs via different endocytic pathways or 2) in the general lysosomal inactivation of the IGF system.

This article has been cited by other articles:

				Y. Jincho, Y. Sotomaru, M. Kawahara, Y. Ono, H. Ogawa, Y. Obata, and T. Kono Identification of Genes Aberrantly Expressed in Mouse Embryonic Stem Cell-Cloned Blastocysts Biol Reprod, April 1, 2008; 78(4): 568 - 576. [Abstract] [Full Text] [PDF]

				C. J. Rosen Circulating IGF-I and Bone Remodeling: New Insights into Old Questions IBMS BoneKEy, January 1, 2008; 5(1): 7 - 15. [Abstract] [Full Text] [PDF]

				C. Heine, B. Koch, S. Storch, A. Kohlschutter, D. N. Palmer, and T. Braulke Defective Endoplasmic Reticulum-resident Membrane Protein CLN6 Affects Lysosomal Degradation of Endocytosed Arylsulfatase A J. Biol. Chem., May 21, 2004; 279(21): 22347 - 22352. [Abstract] [Full Text] [PDF]

				Y. S. Chang, K. Gong, S. Sun, D. Liu, A. K. El-Naggar, F. R. Khuri, W. K. Hong, and H.-Y. Lee Clinical Significance of Insulin-like Growth Factor-binding Protein-3 Expression in Stage I Non-Small Cell Lung Cancer Clin. Cancer Res., December 1, 2002; 8(12): 3796 - 3802. [Abstract] [Full Text] [PDF]

				B. A. Booth, M. Boes, B. L. Dake, K. L. Knudtson, and R. S. Bar IGFBP-3 binding to endothelial cells inhibits plasmin and thrombin proteolysis Am J Physiol Endocrinol Metab, January 1, 2002; 282(1): E52 - E58. [Abstract] [Full Text] [PDF]

				L. Shalamanova, B. Kubler, J.-G. Scharf, and T. Braulke MDCK cells secrete neutral proteases cleaving insulin-like growth factor-binding protein-2 to -6 Am J Physiol Endocrinol Metab, December 1, 2001; 281(6): E1221 - E1229. [Abstract] [Full Text] [PDF]

				H. Yu and T. Rohan Role of the Insulin-Like Growth Factor Family in Cancer Development and Progression J Natl Cancer Inst, September 20, 2000; 92(18): 1472 - 1489. [Abstract] [Full Text] [PDF]

				I. Demori, S. Balocco, A. Voci, and E. Fugassa Increased insulin-like growth factor binding protein-4 expression after partial hepatectomy in the rat Am J Physiol Gastrointest Liver Physiol, March 1, 2000; 278(3): G384 - G389. [Abstract] [Full Text] [PDF]

				A. Pavlova, R. O. Stuart, M. Pohl, and S. K. Nigam Evolution of gene expression patterns in a model of branching morphogenesis Am J Physiol Renal Physiol, October 1, 1999; 277(4): F650 - F663. [Abstract] [Full Text] [PDF]

				P. J. Kaplan, S. Mohan, P. Cohen, B. A. Foster, and N. M. Greenberg The Insulin-like Growth Factor Axis and Prostate Cancer: Lessons from the Transgenic Adenocarcinoma of Mouse Prostate (TRAMP) Model Cancer Res., May 1, 1999; 59(9): 2203 - 2209. [Abstract] [Full Text] [PDF]

				B. A. Booth, M. Boes, B. L. Dake, and R. S. Bar Isolation and characterization of plasmin-generated bioactive fragments of IGFBP-3 Am J Physiol Endocrinol Metab, March 1, 1999; 276(3): E450 - E454. [Abstract] [Full Text] [PDF]

				J. A. Marinaro, E. C. Hendrich, K. S. Leeding, and L. A. Bach HaCaT human keratinocytes express IGF-II, IGFBP-6, and an acid-activated protease with activity against IGFBP-6 Am J Physiol Endocrinol Metab, March 1, 1999; 276(3): E536 - E542. [Abstract] [Full Text] [PDF]

				N. Boulle, A. Logié, C. Gicquel, L. Perin, and Y. Le Bouc Increased Levels of Insulin-Like Growth Factor II (IGF-II) and IGF-Binding Protein-2 Are Associated with Malignancy in Sporadic Adrenocortical Tumors J. Clin. Endocrinol. Metab., May 1, 1998; 83(5): 1713 - 1720. [Abstract] [Full Text]